BFRG Stock Overview
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Bullfrog AI Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.49 |
52 Week High | US$9.50 |
52 Week Low | US$2.36 |
Beta | 0 |
1 Month Change | -10.51% |
3 Month Change | 25.09% |
1 Year Change | 15.56% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -26.68% |
Recent News & Updates
Recent updates
Shareholder Returns
BFRG | US Healthcare Services | US Market | |
---|---|---|---|
7D | -5.2% | -0.2% | 1.3% |
1Y | 15.6% | 2.8% | 29.8% |
Return vs Industry: BFRG exceeded the US Healthcare Services industry which returned 2.8% over the past year.
Return vs Market: BFRG underperformed the US Market which returned 29.8% over the past year.
Price Volatility
BFRG volatility | |
---|---|
BFRG Average Weekly Movement | 22.0% |
Healthcare Services Industry Average Movement | 10.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BFRG's share price has been volatile over the past 3 months.
Volatility Over Time: BFRG's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 6 | Vin Singh | https://www.bullfrogai.com |
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease.
Bullfrog AI Holdings, Inc. Fundamentals Summary
BFRG fundamental statistics | |
---|---|
Market cap | US$20.17m |
Earnings (TTM) | -US$4.75m |
Revenue (TTM) | US$75.00k |
283.6x
P/S Ratio-4.5x
P/E RatioIs BFRG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BFRG income statement (TTM) | |
---|---|
Revenue | US$75.00k |
Cost of Revenue | US$6.00k |
Gross Profit | US$69.00k |
Other Expenses | US$4.82m |
Earnings | -US$4.75m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.78 |
Gross Margin | 92.00% |
Net Profit Margin | -6,339.25% |
Debt/Equity Ratio | 5.7% |
How did BFRG perform over the long term?
See historical performance and comparison